Why you should join AstraZeneca or MedImmune
This is your chance to get involved in a truly exciting mission. At AstraZeneca, we believe that the best way we can help patients is to push the boundaries of science. We uncover the ways diseases work and then discover new, targeted medicines that can change lives.
We commit to areas where we think we can really change the course of medicine. So working here means having the freedom to think big and work together to make the impossible a reality. And every single person who works here has a part to play in our mission.
Whatever your role, when you work with us you can be sure that your work has real purpose.
Vice-President and Head of Personalised Healthcare and Biomarkers, IMED Biotech Unit
Ruth March, PhD, is Vice-President of AstraZeneca’s Personalised Healthcare and Biomarkers function, including over 100 diagnostic and biomarker experts in the UK, US and Sweden.
A member of the senior team leading AstraZeneca’s Innovative Medicines & Early Development, Ruth is accountable for delivering companion diagnostics and validated biomarkers to AstraZeneca drug projects, targeting medicines across all therapy areas to those most likely to benefit.
Director, Molecular Diagnostics Labs and Pharmacogenomics, IMED Biotech Unit
Benoit Destenaves is an expert in personalised medicine and pharmacogenomics with more than 14 years of experience in the biotechnology and pharmaceutical industry.
Benoit specialises in the study of molecular biomarkers (DNA and RNA). He joined AstraZeneca's IMED Biotech unit in 2013 as Director, leading the Molecular Diagnostics labs and Pharmacogenomics. He heads a team of 14 scientists in charge of evaluation technology platforms for companion diagnostics, developing molecular diagnostics in partnership with diagnostic companies and supporting clinical testing. One of the key interests of his group is oncology, with a strong focus on novel approaches (e.g. ctDNA analysis, NGS).